Melanie Ivarsson OBE Joins PhaseV Scientific Advisory Board

Melanie Ivarsson, PhD, OBE, a veteran clinical development leader and former Chief Development Officer at Moderna, has joined the scientific advisory board of PhaseV, a company focused on AI- and machine learning-driven clinical development.

Ivarsson’s appointment aligns with PhaseV’s launch of a new platform aimed at improving the operational efficiency of clinical trials using artificial intelligence.

AI to Support Smarter Clinical Trial Execution

PhaseV’s newly launched ClinOps platform is designed to enhance site selection and performance monitoring in clinical trials. The tool leverages AI to improve speed, accuracy, and operational insight throughout the trial process.

“PhaseV’s groundbreaking AI-driven platform will redefine how clinical trials are designed and executed, with speed, accuracy, and new levels of insight that the industry urgently needs,” said Ivarsson. “It’s a privilege to join such an innovative, ambitious team driving a true paradigm shift in how we bring new therapies to market.”

A Career Spanning Moderna, Takeda, Pfizer, and Eli Lilly

Ivarsson brings nearly 30 years of experience in global clinical development. Prior to her time at Moderna—where she played a key role in the development of one of the first approved COVID-19 vaccines—she led global clinical operations at Takeda. There, she was responsible for trials across a range of therapeutic areas including oncology, neuroscience, rare diseases, and gastrointestinal therapies.

Her earlier roles include senior leadership positions at Pfizer and work in early clinical development at Eli Lilly.

Strategic Addition to Support AI-Driven Clinical Transformation

Raviv Pryluk, PhD, CEO and co-founder of PhaseV, said Ivarsson’s appointment strengthens the company’s scientific and clinical foundation.

“Dr. Ivarsson’s decision to join PhaseV is a powerful endorsement of the impact of our vertical AI solutions for biopharma,” Pryluk said. “Her track record leading complex and high-impact global clinical programs brings unmatched expertise to our mission. Her insights will be invaluable as we continue to expand our ClinOps platform.”

Industry Adoption of PhaseV Technology

According to the company, more than 30 global pharmaceutical, biotech, and clinical research organizations currently use PhaseV’s technology to support clinical programs across 20 therapeutic areas.

The company aims to reshape how clinical trials are designed, managed, and analyzed, with a focus on improving efficiency, speed, and decision-making accuracy.